4//SEC Filing
HIGH SUSANNA GATTI 4
Accession 0000950170-24-073289
CIK 0001818794other
Filed
Jun 12, 8:00 PM ET
Accepted
Jun 13, 9:45 PM ET
Size
10.5 KB
Accession
0000950170-24-073289
Insider Transaction Report
Form 4
HIGH SUSANNA GATTI
Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
2024-06-12$5.54/sh+40,000$221,600→ 188,792 total - Sale
Common Stock
2024-06-12$33.17/sh−26,036$863,614→ 162,756 total - Sale
Common Stock
2024-06-12$33.70/sh−13,964$470,587→ 148,792 total - Exercise/Conversion
Stock option (right to buy)
2024-06-12−40,000→ 100,486 totalExercise: $5.54Exp: 2030-07-30→ Common Stock (40,000 underlying)
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $32.50 to $33.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $33.51 to $34.04, inclusive.
- [F4]Includes 134,629 unvested RSUs.
- [F5]The option was granted on July 31, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on July 31, 2021 and the remaining shares vesting in equal quarterly installments thereafter.
Documents
Issuer
Dyne Therapeutics, Inc.
CIK 0001818794
Entity typeother
Related Parties
1- filerCIK 0001691005
Filing Metadata
- Form type
- 4
- Filed
- Jun 12, 8:00 PM ET
- Accepted
- Jun 13, 9:45 PM ET
- Size
- 10.5 KB